Skip to content
Study details
Enrolling now

Ketamine Trial for Suicidal Patients

Lindsay Maguire, MD
NCT IDNCT06085937ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

50

Study length

about 2 years

Ages

18–65

Locations

2 sites in KS

What this study is about

This trial is testing if low-dose intravenous ketamine can be safely used in the Emergency Department to help people with suicidal thoughts. The goal is to determine whether this treatment is safe and feasible.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Ketamine

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)

Endpoints

Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Secondary: Hospital Length of Stay

Body systems

Psychiatry / Mental Health